Detalhe da pesquisa
1.
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Lancet
; 402(10404): 798-808, 2023 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37451295